While mutations in EFEMP2, ADAM10, SERPINH1, ADAM15, GAS6 and TNXB were detected only in patients with glioma grade 3, mutations in LTBP2, DCN, CRELD1 and HAPLN3 were observed only in patients with glioma grade 4, GBM (Fig. 3, E and H; Supplemental Table S8). This evidence concerns the gene CRELD1 and central nervous system cancer.